Role of the angiotensin II type 1 receptor in preconditioning against infarction

Coronary Artery Disease

Volumn 8, Issue 6, 1997, Pages 343-350

  Nakano, Atsushi ^a   Miura, Tetsuji ^a   Ura, Nobuyuki ^a   Suzuki, Katsuo ^a   Shimamoto, Kazuaki ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiotensin II; AT1 receptor; Infarct size; Preconditioning; Rabbit

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; CANDESARTAN; TETRAZOLIUM;

ANGIOTENSIN BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY PERFUSION; ARTICLE; CONTROLLED STUDY; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; MALE; NONHUMAN; PRESSOR RESPONSE; PRIORITY JOURNAL; RABBIT; REPERFUSION;

EID: 0030864448     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019501-199706000-00003     Document Type: Article

References (39)

1. Miura T, Iimura O: Infarct size limitation by preconditioning: Its phenomenological features and the key role of adenosine. Cardiovasc Res 1993, 27:36-42.
2. Deutsch E, Berger M, Kussmaul W, Hirshfeld JW, Herrmann HC, Lasky WL: Adaptation to ischemia during percutaneous transluminal coronary angioplasty: Clinical, hemodynamic, and metabolic features. Circulation 1990, 82:2044-2051.
3. Yellon DM, Alkhulaifi AM, Pugsley WB: Preconditioning the human myocardium. Lancet 1993, 342:276-277.
4. + channel blocker. Circulation 1994, 90:700-705.
5. Walker DM, Walker JM, Pugsley WB, Pattison CW, Yellon DM: Preconditioning in isolated superfused human muscle. J Mol Cell Cardiol 1995, 27:1349-1357.
6. Kloner RA, Shook T, Przyklenk K, Davis VG, Junio L, Matthews RV, et al.: Previous angina alters in-hospital outcome in TIMI 4. A clinical correlate to preconditioning? Circulation 1995, 91:37-47.
7. + channel? Studies of contractile function following simulated ischemia in an atrial in vitro model. Circ Res 1995, 77:1030-1035.
8. Jenkins DP, Pugsley WB, Alkhulaifi AM, Kemp M, Hooper J, Yellon DM: Ischemic preconditioning reduces troponin T release in patients undergoing coronary artery bypass surgery. Heart 1997, 77:314-318.
9. Liu GS, Thornton J, Van Winkle DM, Stanley AWH, Olsson RA, Downey JM: Protection against infarction afforded by preconditioning is mediated by A1 adenosine receptors in rabbit heart. Circulation 1991, 84:350-356.
10. Thornton JD, Thornton CS, Downey JM: Effect of adenosine receptor blockade: Preventing protective preconditioning depends on time of initiation. Am J Physiol 1993, 265:H504-H508.
11. Goto M, Liu Y, Yang X-M, Ardell JL, Cohen MV, Downey JM: Role of bradykinin in protection of ischemic preconditioning in rabbit hearts. Circ Res 1995, 77:611-621.
12. Schute JJ, Rose E, Yao Z, Gross GJ: Evidence for involvement of opioid receptors in ischemic preconditioning in rat hearts. Am J Physiol 1995, 268:H2157-H2161.
13. Schultz JJ, Hsu AK, Gross GJ: Morphine mimics the cardioprotective effect of ischemic preconditioning via a glibenclamide-sensitive mechanism in the rat heart. Circ Res 1996, 78:1100-1104.
14. Baneerjee A, Locke-Winter C, Rogers KB, Milchell MB, Brew EC, Cairns CB, et al.: Preconditioning against myocardial dysfunction after ischemia and reperfusion by an α1-adrenergic mechanism. Circ Res 1993, 73:656-670.
15. Toyo-oka T, Aizawa T, Suzuki N, Hirata Y, Miyauchi T, Shin WS, et al.: Increased plasma level of endothelin-1 and coronary spasm induction in patients with vasospastic angina pectoris. Circulation 1991, 83:476-483.
16. Remme WJ, Kruyssen DAC. Look MP, Bootsma M, de Leeuw PW: Systemic and cardiac neuroendocrine activation and severity of myocardial ischemia in humans. J Am Coll Cardiol 1994, 23:82-91.
17. Ertl G, Meesmann M, Kochsiek K: On the mechanism of renin release during experimental myocardial ischemia. Eur J Clin Invest 1985, 15:375-381.
18. Baker KM, Booz GW, Dostal DE: Cardiac actions of angiotensin II: Role of an intracardiac renin-angiotensin system. Annu Rev Physiol 1992, 54:227-241.
19. Danser AHJ, van Kats JP, Admiraal PJJ, Derkx FHM, Lamers JMJ, Verdouw PD, et al.: Cardiac renin and angiotensins. Uptake from plasma versus in situ synthesis. Hypertension 1994, 24:37-48.
20. Pfeffer MA, Lamas GA, Vaughan DE, Pansi AF, Braunwald E: Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction. N Engl J Med 1988, 319:80-86.
21. Liu Y, Tsuchida A, Cohen MV, Downey JM: Pretreatment with angiotensin II activates protein kinase C and limits myocardial infarction in isolated rabbit hearts. J Mol Cell Cardiol 1995, 27:883-892.
22. Sakamoto J, Miura T, Goto M, limura O: Limitation of myocardial infarct size by adenosine A1 receptor activation is abolished by protein kinase C inhibitors in the rabbit. Cardiovasc Res 1995, 29:682-685.
23. Ytrehus K, Liu Y, Downey JM: Preconditioning protects ischaemic rabbit heart by protein kinase C activation. Am J Physiol 1994, 266:H1145-H1152.
24. Shibouta Y, Inada y, Ojima M, Wada T, Noda M, Sanada T, et al.: Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-[2′-(1H-tetrazol-5-yl)biphenyl-4-yl]-1H-benzimidazole-7- carboxylic acid (CV-11794), and its prodrug (+/-)-1-(cyclohexyloxycarbonyloxy)-ethyl 2-ethoxy-1-[[2′-(1 H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1 H-benzimidazole-7-carboxylate (TCV-116). J Pharmacol Exp Thet 1993, 266:114-120.
25. Timmermans PBMWM, Wong PC, Chiu AT, Erblin WF, Benfield P, Carini D, et al.: Angiotensin II receptor and angiotensin II receptor antagonists. Pharmacol Rev 1993, 45:205-251.
26. Linz W, Wiemer G, Gohlke P, Unger T, Scholkens BA: Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev 1995, 47:25-49.
27. Miura T, Goto M, Miki T, Sakamoto J, Shimamoto K, limura O: Glibenclamide, a blocker of ATP-sensitive potassium channels, abolishes infarct size limitation by preconditioning in rabbits anesthetized with xylazine/pentobarbital but not with pentobarbital alone. J Cardiovasc Pharmacol 1995, 25:531-538.
28. Nishitani T, Shimamolo K: A very sensitive direct radioimmunoassay of human plasma angiotensin II and its clinical application [in Japanese]. Sapporo Med J 1987, 56:649-657.
29. Miura T, Ogawa T, Iwamoto T, Shimamoto K, limura O: Dipyridamole potentiates the myocardial infarct size-limiting effect of ischemic preconditioning. Circulation 1992, 86:979-985.
30. Diaz RJ, Sandhu R, Wilson GJ: Participation of angiotensin II receptors in ischemic preconditioning [abstract]. J Mol Cell Cardiol 1995, 27:A43.
31. Przyklenk K, Kloner RA: 'Cardioprotection' by ACE-inhibitors in acute myocardial ischemia and snfarctioń Basic Res Cardiol 1993, 88 (suppl 1):154.
32. Tian R, Neubauer S, Pulzer F, Haas U, Ertl G: Angiotensin I conversion and coronary constriction by angiotensin II in ischemic and hypoxic isolated rat hearts. Zur J Pharmacol 1991, 203:71-77.
33. Sadoshima J, Xu Y, Slayter HS, Izumo S: Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro. Cell 1993, 75:977-984.
34. Richard V, Ghaleh B, Bordeaux A, Giudicelli J-F: Comparison of the effects of EXP3174, and angiotensin II antagonist and enalaprilat on myocardial infarct size in anaesthetized dogs. Br J Pharmacol 1993, 110:969-974.
35. Miki T, Miura T, Shimamoto K, Urabe K, Sakamoto J, (Iimura O: Do angiotensin converting enzyme inhibitors limit myocardial infarct sizé Clin Exp Pharmacol Physiol 1993, 20:429-434.
36. Miki T, Miura T, Ura N, Ogawa T, Suzuki K, Shimamoto K, Iimura O: Captopril potentiates the myocardial infarct size-limiting effect of ischemic preconditioning through bradykinin B2 receptor activation. J Am Coll Cardiol 1996, 28:1616-1522.
37. Daniel HB, Carson R, Ballard KD, Thomas GR, Privitera PJ: Effect of captopril on limiting infarct size in conscious dogs. J Cardiovasc Pharmacol 1984, 6:1043-1047.
38. Martonrana PA, Kettenbach B, Breipohl G, Linz W, Scholkens BA: Reduction of infarct size by local angiotensin-converting enzyme inhibition is abolished by a bradykinin antagonist Eur J Pharmacol 1990, 182:395-396.
39. Hartman JC, Wall TM, Hullinger TG, Shebuski RJ: Reduction of myocardial infarct size in rabbits by ramiprilat: Reversal by the bradykinin antagonist Hoe 140. J Cardiovasc Pharmacol 1993, 21:996-1003.